Table 1.
Patient and tumour characteristics (N = 36, %).
| Characteristic | Overall (n=36) | Pre-treatment | p | Post-treatment | p | ΔSMI (%)/50 days | p | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia (n=7) | Non-sarcopenia (n=29) | Sarcopenia (n=13) | Non-sarcopenia (n=23) | SML (n=8) | Non-SML (n=28) | |||||
| Age (years) | 1.000* | 0.475* | 1.000* | |||||||
| ≤50 | 11 (30.56) | 2 (28.57) | 9 (31.03) | 5 (38.46) | 6 (26.09) | 2 (25.00) | 9 (32.14) | |||
| >50 | 25 (69.44) | 5 (71.43) | 20 (68.97) | 8 (61.54) | 17 (73.91) | 6 (75.00) | 19 (67.86) | |||
| ECOG | 0.073* | 0.016* | 0.209* | |||||||
| 0 | 30 (83.33) | 4 (57.14) | 26 (89.66) | 8 (61.54) | 22 (95.65) | 5 (62.50) | 25 (89.29) | |||
| 1 | 6 (16.67) | 3 (42.86) | 3 (10.34) | 5 (38.46) | 1 (4.35) | 3 (37.50) | 3 (10.71) | |||
| Gender | 0.650* | 0.153* | 0.961* | |||||||
| Male | 25 (69.44) | 4 (57.14) | 21 (72.41) | 7 (53.85) | 18 (78.26) | 5 (62.50) | 20 (71.43) | |||
| Female | 11 (30.56) | 3 (42.86) | 8 (27.59) | 6 (46.15) | 5 (21.74) | 3 (37.50) | 8 (28.57) | |||
| Lesion site | 0.318* | 0.067* | 0.712* | |||||||
| Upper 1/3 | 13 (36.11) | 1 (14.29) | 12 (41.38) | 1 (7.69) | 12 (52.17) | 2 (25.00) | 11 (39.28) | |||
| Middle 1/3 | 9 (25.00) | 3 (42.86) | 6 (20.69) | 6 (46.15) | 3 (13.04) | 2 (25.00) | 7 (25.00) | |||
| Lower 1/3 | 14 (38.89) | 3 (42.86) | 11 (37.93) | 6 (46.15) | 8 (34.78) | 4 (50.00) | 10 (35.71) | |||
| Borrmann type | 1.000* | 1.000* | 1.000* | |||||||
| I–II | 8 (22.22) | 1 (14.29) | 7 (24.13) | 3 (23.08) | 5 (21.74) | 2 (25.00) | 6 (21.43) | |||
| III–IV | 28 (77.78) | 6 (85.71) | 22 (75.86) | 10 (76.92) | 18 (78.26) | 6 (75.00) | 22 (78.57) | |||
| Histological | 0.573* | 0.645* | 0.858* | |||||||
| High-moderate | 6 (16.67) | 2 (28.57) | 4 (13.79) | 3 (23.08) | 3 (13.04) | 2 (25.00) | 4 (14.29) | |||
| Low | 30 (83.33) | 5 (71.43) | 25 (86.21) | 10 (76.92) | 20 (86.96) | 6 (75.00) | 24 (85.71) | |||
| cT staging | 1.000* | 1.000* | 1.000* | |||||||
| T3 | 6 (16.67) | 1 (14.29) | 5 (17.24) | 2 (15.38) | 4 (17.39) | 1 (12.50) | 5 (17.86) | |||
| T4 | 30 (83.33) | 6 (85.71) | 24 (82.76) | 11 (84.62) | 19 (82.61) | 7 (87.50) | 23 (82.14) | |||
| cN staging | 0.333* | 0.693* | 1.000* | |||||||
| N1–N2 | 9 (25.00) | 3 (42.86) | 6 (20.69) | 4 (30.77) | 5 (21.74) | 2 (25.00) | 7 (25.00) | |||
| N3 | 27 (75.00) | 4 (57.14) | 23 (79.31) | 9 (69.23) | 18 (78.26) | 6 (75.00) | 21 (75.00) | |||
| Lesion size (cm) | 1.000* | 1.000* | 0.643* | |||||||
| <5 | 9 (25.00) | 2 (28.57) | 7 (24.13) | 3 (23.08) | 6 (26.09) | 1 (12.50) | 8 (28.57) | |||
| ≥5 | 27 (75.00) | 5 (71.43) | 22 (75.86) | 10 (76.92) | 17 (73.91) | 7 (87.50) | 20 (71.43) | |||
ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; SML, Significant muscle loss. *Fisher’s exact test.